NCT02339922 2026-03-05
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
University of Washington
Phase 2 Active not recruiting
Clinical Trials
9 trialsNCT03506373 2026-03-05
Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia
Mayo Clinic
Phase 2 Terminated
NCT04463953 2026-02-11
Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Completed
NCT04047797 2025-04-20
Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02924272 2025-03-12
Ixazomib Rollover Study
Takeda
Phase 2 Completed
NCT03616782 2023-10-06
Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL)
Kosin University Gospel Hospital
Phase 2 Recruiting
NCT02169791 2021-09-02
Nonmyeloablative Haploidentical Transplant Followed by MLN9708
Northside Hospital, Inc.
Phase 2 Completed
NCT02400437 2020-09-02
Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02158975 2017-11-13
Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas
University of Michigan Rogel Cancer Center
Phase 2 Completed